PMC:5848821 / 9631-12681 JSONTXT

{"project":"testtesttest","denotations":[{"id":"T23","span":{"begin":2241,"end":2245},"obj":"Body_part"},{"id":"T24","span":{"begin":2257,"end":2268},"obj":"Body_part"},{"id":"T26","span":{"begin":2280,"end":2286},"obj":"Body_part"},{"id":"T28","span":{"begin":2358,"end":2366},"obj":"Body_part"},{"id":"T29","span":{"begin":2401,"end":2417},"obj":"Body_part"},{"id":"T30","span":{"begin":2429,"end":2447},"obj":"Body_part"},{"id":"T31","span":{"begin":2458,"end":2471},"obj":"Body_part"},{"id":"T32","span":{"begin":2481,"end":2494},"obj":"Body_part"},{"id":"T33","span":{"begin":2516,"end":2520},"obj":"Body_part"},{"id":"T34","span":{"begin":2532,"end":2543},"obj":"Body_part"},{"id":"T36","span":{"begin":2569,"end":2580},"obj":"Body_part"},{"id":"T37","span":{"begin":2592,"end":2597},"obj":"Body_part"},{"id":"T38","span":{"begin":2607,"end":2620},"obj":"Body_part"},{"id":"T39","span":{"begin":2632,"end":2637},"obj":"Body_part"}],"attributes":[{"id":"A23","pred":"uberon_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A24","pred":"uberon_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/UBERON_0002406"},{"id":"A25","pred":"uberon_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/UBERON_0002407"},{"id":"A26","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0000977"},{"id":"A27","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0003390"},{"id":"A28","pred":"uberon_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/UBERON_0000210"},{"id":"A29","pred":"uberon_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/UBERON_0001103"},{"id":"A30","pred":"uberon_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/UBERON_0001585"},{"id":"A31","pred":"uberon_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/UBERON_0016403"},{"id":"A32","pred":"uberon_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/UBERON_0001884"},{"id":"A33","pred":"uberon_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A34","pred":"uberon_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/UBERON_0002406"},{"id":"A35","pred":"uberon_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/UBERON_0002407"},{"id":"A36","pred":"uberon_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/UBERON_0001015"},{"id":"A37","pred":"uberon_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/UBERON_0000947"},{"id":"A38","pred":"uberon_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/UBERON_0013768"},{"id":"A39","pred":"uberon_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/UBERON_0000947"}],"text":"Surgery for pleural disease of thymic epithelial tumours: surgical approach, type and completeness of resection\nDifferent surgical approaches were chosen to resect TETs with pleural involvement (Table 2). For the resection of pleural disease, EPP was performed in 26.5%, TP in 15.2% and LP in 58.3% of patients. EPP, TP and LP were performed in 32 cases (29.9%), 13 cases (12.1%, including 1 case of pleurectomy/decortication [P/D]) and 62 cases (57.9%) for primary pleural surgery (Scenario 2), respectively. In patients with pleural surgery for recurrence (Scenario 1, first pleural surgery) EPP, TP and LP were carried out in 8 patients (18.2%) and 10 patients (22.7%, including 3 patients with P/D) and 26 patients (59.1%), respectively (missing information: 1 patient). Completeness of resection was pathologically confirmed in 76 (71%, R0), incomplete resection in 16 (15%, R1) and 15 (14%, R2) for primary pleural surgery. Completeness of resection for recurrent pleural surgery was reported as: 40 (90.9%, R0), 1 (2.3%, R1) and 2 (4.5%, R2), respectively (missing information: 2 patients).\nTable 2 Treatment modalities\nn = 152 n (%)\nPreoperative treatment\n Neoadjuvant 67/107 (62.6)\n  Chemotherapy 59/67 (88.1)\n  Radiotherapy 5/67 (7.5)\n  Radiotherapy and chemotherapy 3/67 (4.4)\n Pseudo-neoadjuvant 15/45 (33.3)\n  Chemotherapy 14/15 (93.3)\n  Radiotherapy 1/15 (6.7)\n  Radiotherapy and chemotherapy 0/15 (0.0)\nResponse to preoperative therapy\n Neoadjuvant\n  Stable disease 5 (7.5)\n  Partial response 48 (71.6)\n  Progression 3 (3.9)\n  No information 11 (16.4)\n Pseudo-neoadjuvant\n  Stable disease 1 (6.6)\n  Partial response 7 (46.6)\n  Progression 0 (0.0)\n  No information 7 (46.6)\nPostoperative treatment\n Adjuvant 68/107 (63.6)\n  Chemotherapy 5/68 (7.3)\n  Radiotherapy 49/68 (72.1)\n  Radiotherapy and chemotherapy 14/68 (20.6)\n Pseudo-adjuvant 10/45 (22.2)\n  Chemotherapy 5/10 (50.0)\n  Radiotherapy 4/10 (40.0)\n  Radiotherapy and chemotherapy 1/10 (10.0)\nSurgical approach\n Thoracotomy 61 (40.4)\n Sternotomy 65 (43.0)\n Clamshell 6 (4.0)\n Hemi-clamshell 16 (10.6)\n Video-assisted thoracic surgery 3 (2.0)\nType of pleural surgery\n Extrapleural peumonectomy 40 (26.5)\n Local pleurectomy 88 (15.2)\n Total pleurectomy 23 (58.3)\nInvasion\n Lung 91 (65.9)\n Pericardium 76 (53.9)\n Pleura\n  Parietalis 40 (28.2)\n  Visceralis 6 (4.2)\n  Diaphragmatic 11 (7.7)\n  Parietal/visceral/diaphragmatic 67 (47.2)\n Diaphragm muscle 39 (27.7)\n Superior vena cava 10 (7.1)\n Thoracic wall 9 (6.4)\n Phrenic nerve 33 (23.4)\nAdherence\n Lung 68 (47.6)\n Pericardium 56 (39.2)\n Diaphragmatic musculature 41 (28.7)\n Aorta 8 (5.6)\n Great vessels other than aorta 12 (8.4)\nResidual tumour\n R0 116 (77.3)\n R1 17 (11.3)\n R2 17 (11.3)\nRecurrencea 115 (100)\n No 56 (48.7)\n Yes 59 (51.3)\nRecurrence type 59 (100)\n Local 15/59 (25.4)\n Regional 30/59 (50.8)\n Distant 9/59 (15.3)\n Regional and distant 5/59 (8.5)\na Recurrences only after R0 resection were included in the analysis.\nThe mean number of resected pleural nodules was 7.7 [range 1–90]. Tumour invasion/adherence (Table 2)."}